Tumorigenesis and Neoplastic Progression Syntenic Relationships between Genomic Profiles of Fiber-Induced Murine and Human Malignant Mesothelioma

From INSERM, U674,* Paris, France; the Université Paris Descartes, UMR-S674, Paris, France; the Ligue Nationale Contre le Cancer, Paris, France; INSERM, U830, Paris, France; Institut Curie, Centre de Recherche, Paris, France; the Laboratoire d’Ecotoxicology, Université du Havre, UFR de Sciences et Techniques, UPRES-EA3222, Le Havre, France; the Service de Pneumologie et de Pathologie Professionnelle, Hôpital Intercommunal de Créteil, Créteil, France; INSERM, U955, Equipe 4, IMRB, Créteil, France; the Faculté de Médecine, Université Paris-Est, Créteil, France; the Service d’Histologie et de Biologie Tumorale, AP-HP, GHU Est, Hôpital Tenon, Paris, France; the Université Pierre et Marie Curie, Paris, France; Service d’Anatomie Pathologique, Hôpital de la Côte de Nacre, Caen, France; INSERM, ERI3, Caen, France; and the House Ear Institute, Center for Neural Tumor Research, Los Angeles, California

[1]  B. Christensen,et al.  Integrated profiling reveals a global correlation between epigenetic and genetic alterations in mesothelioma. , 2010, Cancer research.

[2]  M. Goldberg,et al.  Possible effect of environmental exposure to asbestos on geographical variation in mesothelioma rates , 2010, Occupational and Environmental Medicine.

[3]  J. Zavadil,et al.  Pro-tumorigenic Effects of miR-31 Loss in Mesothelioma* , 2010, The Journal of Biological Chemistry.

[4]  Takashi Takahashi,et al.  Homozygous deletion of CDKN2A/2B is a hallmark of iron-induced high-grade rat mesothelioma , 2010, Laboratory Investigation.

[5]  Craig A. Poland,et al.  Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma , 2010, Particle and Fibre Toxicology.

[6]  F. Favero,et al.  MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. , 2010, American journal of respiratory cell and molecular biology.

[7]  G. Mardon,et al.  The Dachshund gene in development and hormone-responsive tumorigenesis , 2010, Trends in Endocrinology & Metabolism.

[8]  S. Jhanwar,et al.  The promyelocytic leukemia zinc finger gene, PLZF, is frequently downregulated in malignant mesothelioma cells and contributes to cell survival , 2009, Oncogene.

[9]  G. Berx,et al.  Involvement of members of the cadherin superfamily in cancer. , 2009, Cold Spring Harbor perspectives in biology.

[10]  A. Nicholson,et al.  CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma—A miRNA microarray analysis , 2009, Genes, chromosomes & cancer.

[11]  P. Valberg,et al.  Ionizing radiation: a risk factor for mesothelioma , 2009, Cancer Causes & Control.

[12]  A. Hui,et al.  Progressive increase of genetic alteration in urinary bladder cancer by combined allelotyping analysis and comparative genomic hybridization. , 2009, International journal of oncology.

[13]  J. Testa,et al.  Activated TNF-α/NF-κB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice , 2009, Proceedings of the National Academy of Sciences.

[14]  K. O'Byrne,et al.  In Arrayed Ranks: Array Technology in the Study of Mesothelioma , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[15]  M. Cesta,et al.  Inhaled multiwalled carbon nanotubes potentiate airway fibrosis in murine allergic asthma. , 2009, American journal of respiratory cell and molecular biology.

[16]  R. Lucito,et al.  Genomic events associated with progression of pleural malignant mesothelioma , 2009, International journal of cancer.

[17]  Akihiko Hirose,et al.  Induction of mesothelioma by a single intrascrotal administration of multi-wall carbon nanotube in intact male Fischer 344 rats. , 2009, The Journal of toxicological sciences.

[18]  H. Burris,et al.  A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer , 2009, Investigational New Drugs.

[19]  Eun‐Kee Park,et al.  Asbestos-related occupational lung diseases in NSW, Australia and potential exposure of the general population. , 2008, Industrial health.

[20]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[21]  M. Esteller,et al.  Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer , 2008, Epigenetics.

[22]  J. Maris,et al.  CHD5, a Tumor Suppressor Gene Deleted From 1p36.31 in Neuroblastomas , 2008, Journal of the National Cancer Institute.

[23]  M. Daidone,et al.  Multiple Mechanisms of Telomere Maintenance Exist and Differentially Affect Clinical Outcome in Diffuse Malignant Peritoneal Mesothelioma , 2008, Clinical Cancer Research.

[24]  Craig A. Poland,et al.  Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. , 2008, Nature nanotechnology.

[25]  M. J. van de Vijver,et al.  A conditional mouse model for malignant mesothelioma. , 2008, Cancer cell.

[26]  Neil A. Miller,et al.  Transcriptome sequencing of malignant pleural mesothelioma tumors , 2008, Proceedings of the National Academy of Sciences.

[27]  N. Probst-Hensch,et al.  PTEN expression is a strong predictor of survival in mesothelioma patients. , 2008, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[28]  B. Christensen,et al.  Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma , 2008, Carcinogenesis.

[29]  J. Kanno,et al.  Induction of mesothelioma in p53+/- mouse by intraperitoneal application of multi-wall carbon nanotube. , 2008, The Journal of toxicological sciences.

[30]  A. Nicholson,et al.  Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH , 2007, Cytogenetic and Genome Research.

[31]  L. Hesson,et al.  Evaluation of the 3p21.3 tumour-suppressor gene cluster , 2007, Oncogene.

[32]  M. Jaurand,et al.  Clinico-pathological features and somatic gene alterations in refractory ceramic fibre-induced murine mesothelioma reveal mineral fibre-induced mesothelioma identities. , 2007, Carcinogenesis.

[33]  D. Rickman,et al.  Pre-TCR expression cooperates with TEL-JAK2 to transform immature thymocytes and induce T-cell leukemia. , 2007, Blood.

[34]  P. Hall,et al.  Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  O. Mariani,et al.  JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. , 2007, Cancer cell.

[36]  H. Tagawa,et al.  Genomic profiling of malignant pleural mesothelioma with array‐based comparative genomic hybridization shows frequent non‐random chromosomal alteration regions including JUN amplification on 1p32 , 2007, Cancer science.

[37]  H. Vogel,et al.  CHD5 Is a Tumor Suppressor at Human 1p36 , 2007, Cell.

[38]  Marius Žemaitis,et al.  Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. , 2006, Lung cancer.

[39]  Nicolas Stransky,et al.  VAMP: Visualization and analysis of array-CGH, transcriptome and other molecular profiles , 2006, Bioinform..

[40]  J. Tward,et al.  The risk of secondary malignancies over 30 years after the treatment of non‐Hodgkin lymphoma , 2006, Cancer.

[41]  Emmanuel Barillot,et al.  Spatial normalization of array-CGH data , 2006, BMC Bioinformatics.

[42]  P. Carroll,et al.  Bladder cancer stage and outcome by array-based comparative genomic hybridization. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  F. Galateau-Sallé,et al.  The French National Mesothelioma Surveillance Program , 2006, Occupational and Environmental Medicine.

[44]  A. Kane.  Animal Models of Malignant Mesothelioma , 2006, Inhalation toxicology.

[45]  L. Beckett,et al.  Residential proximity to naturally occurring asbestos and mesothelioma risk in California. , 2005, American journal of respiratory and critical care medicine.

[46]  B. Robinson,et al.  Advances in malignant mesothelioma. , 2005, The New England journal of medicine.

[47]  S. Jhanwar,et al.  A mouse model recapitulating molecular features of human mesothelioma. , 2005, Cancer research.

[48]  M. Ladanyi.  Implications of P16/CDKN2A deletion in pleural mesotheliomas. , 2005, Lung cancer.

[49]  Emmanuel Barillot,et al.  Analysis of array CGH data: from signal ratio to gain and loss of DNA regions , 2004, Bioinform..

[50]  S. Ozaki,et al.  Malignant pleural mesothelioma in parts of Japan in relationship to asbestos exposure. , 2004, Industrial health.

[51]  A. Sandberg.  Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: lipoma. , 2004, Cancer genetics and cytogenetics.

[52]  R. Weinberg,et al.  Comparative biology of mouse versus human cells: modelling human cancer in mice , 2003, Nature Reviews Cancer.

[53]  V. Broaddus,et al.  c-Jun N-terminal Kinase Contributes to Apoptotic Synergy Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand plus DNA Damage in Chemoresistant, p53 Inactive Mesothelioma Cells* , 2003, Journal of Biological Chemistry.

[54]  L. Pitts,et al.  Neurofibromatosis 2 and malignant mesothelioma. , 2002, Neurology.

[55]  K. Müller,et al.  Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases , 2002, The Journal of pathology.

[56]  G. Gordon,et al.  Alterations of the p16(INK4) locus in human malignant mesothelial tumors. , 2002, Carcinogenesis.

[57]  K. Yokoyama,et al.  Assessment of the mutations of p53 suppressor gene and Ha- and Ki-ras oncogenes in malignant mesothelioma in relation to asbestos exposure: a study of 12 American patients. , 2002, Industrial health.

[58]  F. Galateau-Sallé,et al.  Expression of Telomerase Reverse Transcriptase (TERT) in Malignant Mesotheliomas , 2002, The American journal of surgical pathology.

[59]  S. Jhanwar,et al.  Loss of heterozygosity analysis defines a 3-cM region of 15q commonly deleted in human malignant mesothelioma , 2001, Oncogene.

[60]  J. Kere,et al.  Deletions at 14q in malignant mesothelioma detected by microsatellite marker analysis , 1999, British Journal of Cancer.

[61]  C. Magnani,et al.  Asbestos and cancer: An overview of current trends in Europe. , 1999, Environmental health perspectives.

[62]  S. Jhanwar,et al.  Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma. , 1999, Cancer research.

[63]  T. H. van der Kwast,et al.  The gene for the cyclin‐dependent‐kinase‐4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma , 1998, International journal of cancer.

[64]  K. Pelin,et al.  Gains and losses of DNA sequences in malignant mesothelioma by comparative genomic hybridization. , 1996, Cancer genetics and cytogenetics.

[65]  J. Fletcher,et al.  Codeletion of p15 and p16 in primary malignant mesothelioma. , 1995, Oncogene.

[66]  J. Minna,et al.  Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. , 1995, Cancer research.

[67]  J. Pairon,et al.  Pleural mesothelioma and exposure to asbestos: evaluation from work histories and analysis of asbestos bodies in bronchoalveolar lavage fluid or lung tissue in 131 patients. , 1994, Occupational and environmental medicine.

[68]  S. Jhanwar,et al.  Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. , 1993, Cancer research.

[69]  T. H. van der Kwast,et al.  Cytogenetic analysis of malignant mesothelioma. , 1990, Cancer genetics and cytogenetics.

[70]  S. Knuutila,et al.  Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma. , 1989, British Journal of Cancer.

[71]  R. Stahel,et al.  Chromosome changes in malignant mesothelioma. , 1986, Cancer genetics and cytogenetics.

[72]  J. Testa,et al.  Somatic genetic alterations in human malignant mesothelioma (review). , 1999, International journal of oncology.

[73]  S. Knuutila,et al.  Comparative genomic hybridization study on pooled DNAs from tumors of one clinical-pathological entity. , 1998, Cancer genetics and cytogenetics.

[74]  J. Vermeesch,et al.  A physical map of the region spanning the chromosome 12 translocation breakpoint in a mesothelioma with a t(X;12)(q22;p13). , 1995, Cytogenetics and cell genetics.

[75]  B. Gylseth,et al.  Occupational exposure and regional variation of malignant mesothelioma in Norway, 1970-79. , 1986, American journal of industrial medicine.